HistoIndex Pte.Ltd. property. All Rights Reserved Confidential “Future of Biomedicine” Industry Day University of Glasgow 24 th Sept 2015

HISTOINDEX – BRINGING DIAGNOSIS INTO BIOPSY World’s first fully-automated, 3-D, quantitative, laser-based imaging system for tissue diagnostic HistoIndex Pte.Ltd. property. All Rights Reserved Confidential

GLOBAL TISSUE DIAGNOSTICS MARKET 1 Fastest growth segment with a compounded annual growth rate (CAGR) of 12% in the entire in vitro diagnostics (IVD) market Fastest growth segment with a compounded annual growth rate (CAGR) of 12% in the entire in vitro diagnostics (IVD) market Global market for tissue diagnostic products in 2012: US$2.4 billion; expected to reach US$6.74 billion by 2020 Global market for tissue diagnostic products in 2012: US$2.4 billion; expected to reach US$6.74 billion by % of total global demand to originate from US/EU in 2014; APAC/ROTW to increase to almost 36% by % of total global demand to originate from US/EU in 2014; APAC/ROTW to increase to almost 36% by Carson, Jennifer. "Analysis of the Global Tissue Diagnostics Market." Frost & Sullivan, Nov Carson, Jennifer. "Analysis of the Global Tissue Diagnostics Market." Frost & Sullivan, Nov HistoIndex Pte.Ltd. property. All Rights Reserved Confidential

3 BIG PREDICTIONS 1 1.Convergence of different medical technologies - integrated diagnostics 2.Pathology will transit toward a collaboration with clinical next generation sequencing to enable a combination of pathology and genomic information 3.The evolution of digital pathology, tele-pathology, and virtual consultation, the outpouring of data from pathology laboratories will necessitate cloud storage platforms 1 Carson, Jennifer. "Analysis of the Global Tissue Diagnostics Market." Frost & Sullivan, Nov Carson, Jennifer. "Analysis of the Global Tissue Diagnostics Market." Frost & Sullivan, Nov HistoIndex Pte.Ltd. property. All Rights Reserved Confidential

WHAT ARE CUSTOMERS LOOKING FOR? PRICE SPEED TARGET CUSTOMER SIZE QUANTIFICATION ACCURACY SPECIFIC SENSITIVE OBJECTIVE HistoIndex Pte.Ltd. property. All Rights Reserved Confidential

WHAT DO WE OFFER? HistoIndex Pte.Ltd. property. All Rights Reserved Confidential How did the disease progress/r egress? Why did that happen? When is treatment needed? What treatment to give? CLOUD GENESIS ® LAENNEC™ DISEASE-SPECIFIC DIAGNOSIS Cloud-based Integrated Diagnostics leading to Personalized Treatment

HOW IT WORKS LASER cells ECM Improvement in accuracy of tissue diagnosis from 65% to more than 95% Bedossa et al., Hepatology 20, (1994); Gronbaek et al., Journal of Viral Hepatitis 9, (2002); Theodossi et al., Gastroenterology 79, (1980); Theodossi et al., Gut 35, (1994); Westin et al., Liver 19, (1999) He et al., Journal of Biomedical Optics, 15(5) , Bredfeldt et al., Journal of Pathology Informatics, 5(1), 28, 2014 Raja et al., Journal of Biomedical Optics 15(5) , Gailhouste et al., Journal of Hepatology 52, , Asselah et al, Journal of Hepatology 61, , Tai et al., Hepatology 50(4) 1093, Tai et al., Journal of Biomedical Optics, 14(4) , Xu et al., Journal of Hepatology, 61, , HistoIndex Pte.Ltd. property. All Rights Reserved Confidential

REVOLUTIONARY TECHNOLOGY Stage 1 Stage 2 Stage 3 Stage 4 HistoIndex Stain-Free Stage 1.2 Stage 2.5 Stage 3.1 Stage 4.7 Current Method HistoIndex Pte.Ltd. property. All Rights Reserved Confidential

KEY BENEFITS 1 – 3 days Sample Staining Imaging Staging Diagnosis 0.5 – 1 hr Diagnosis HistoIndex Stain-free Technology HistoIndex Stain-free Technology Sample Patients (Hospitals and Clinics): Patients (Hospitals and Clinics): Same day results – greater accuracy & efficiency Same day results – greater accuracy & efficiency Users (Researchers, Drug companies & CROs): Users (Researchers, Drug companies & CROs): Better specificity & sensitivity Better specificity & sensitivity A "translational" program to measure drug efficacy from the beginning of preclinical studies to the end of the clinical trial Insurance/Enterprises: Insurance/Enterprises: Early detection and prediction, due to backend database Early detection and prediction, due to backend database HistoIndex Pte.Ltd. property. All Rights Reserved Confidential

WE HAVE MADE THIS ROBUST AND SIMPLE From this….. HistoIndex Pte.Ltd. property. All Rights Reserved Confidential

WE HAVE MADE THIS ROBUST AND SIMPLE To THIS….. HistoIndex Pte.Ltd. property. All Rights Reserved Confidential

WHAT IS THIS NEW STANDARD? Hardware Genesis ® 200  Multi-photon microscope utilizing a high power laser  Customized optics  Fully automated  One-touch operation  Unstained tissues  Multi-organ capabilities Computer-assisted tissue diagnostic system HISTOINDEX is setting a NEW STANDARD! Software FibroIndex™ + LiverCloud™  Quantification for decision support database  3D visualization  Cloud-based database & online assessment HistoIndex Pte.Ltd. property. All Rights Reserved Confidential

GLOBAL PRESENCE Physical units placement Clinical/Research sites with samples sending to HistoIndex’s global Imaging Service Centres HistoIndex Pte.Ltd. property. All Rights Reserved Confidential

PRODUCTS …20+ Organs Lung Skin Liver Kidney Single Organ Genesis ® 100 LiverCloud™ Launched in Jun 2015 Research use only (2013) Production ceased (2012) Database dev’mnt Genesis ® 200 Multiple Organs Online Assessment HistoIndex Pte.Ltd. property. All Rights Reserved Confidential Regulatory in progress Laennec™ Clinical Diagnosis Selling for research use

CUSTOMERS, CLIENTS & 4 OTHER Cs Clinical Research: Tool is most flexible and useful; no regulatory approval needed Consumables: Glass slide, optical fiber Consumables: Glass slide, optical fiber Clinical Application: Cloud services, gold standard for liver fibrosis diagnosis Clinical Application: Cloud services, gold standard for liver fibrosis diagnosis Consumers: Skin diagnostics, household products HistoIndex Pte.Ltd. property. All Rights Reserved Confidential

SUMMARY 1.Maximum impact & profit margin through HistoIndex existing global Imaging Service Centres in US, EU & Asia 2.Clinical Research drives Clinical Application 3.Clinical Application drives Clinical Integrative Diagnostics Platform 4.We have an unique product & business model 5.This is NOT only a liver story 6.Liver, Kidney, Lungs, Heart, Cancers, Skin, Cosmetics 7.Changing the way diagnostics are performed and  Treatments developed  Creating a new gold standard 8.10 Years from now, everyone will be touched by HistoIndex HistoIndex Pte.Ltd. property. All Rights Reserved Confidential

HISTOINDEX PTE LTD Contact: GIDEON HO Ph.D., M.Eng. Chief Executive Officer to: Website: Services: HistoIndex Pte.Ltd. property. All Rights Reserved Confidential